Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines.
Vaccine
; 38(49): 7702-7707, 2020 11 17.
Article
in English
| MEDLINE | ID: covidwho-867163
ABSTRACT
Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated viral vaccines. This will help key stakeholders assess potential safety issues and understand the benefit-risk of such vaccines. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed live-attenuated viral vaccines.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Vaccines, Attenuated
/
Viral Vaccines
/
Drug Evaluation, Preclinical
Type of study:
Prognostic study
Topics:
Traditional medicine
/
Vaccines
Limits:
Humans
Language:
English
Journal:
Vaccine
Year:
2020
Document Type:
Article
Affiliation country:
J.vaccine.2020.09.042
Similar
MEDLINE
...
LILACS
LIS